Back to News
Market Impact: 0.25
Retension Pharmaceuticals, TRex Bio file for US IPO as biotech momentum continues
Source: reuters.com
IPOs & SPACsHealthcare & Biotech
Drug developers Retension Pharmaceuticals and TRex Bio filed for U.S. IPOs on Friday, adding to the biotech sector's fall issuance pipeline. The filings signal continued receptivity for biotech listings, though no offering sizes, valuations, or pricing timelines were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Japan has record 100,000 people aged over 100: How societies are ageing
- Exclusive-Anthropic considers releasing new AI model ahead of IPO, sources say
- Anthropic selects Accenture as first embedded evaluator to help implement Amodei's slowdown proposal
- ProEnergy eyes $40 billion to $50 billion valuation in US IPO
- Anthropic delays IPO staging to November amid AI fears, WSJ says
- Anthropic quietly sets up biology lab as it ramps AI drug program: Reuters
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Write an Investment Memo with AI: A Decision-Record Template
- Best AI to Write Earnings Notes for Sell-Side Analysts